Welcome to our dedicated page for Viracta Therapeutics news (Ticker: VIRX), a resource for investors and traders seeking the latest updates and insights on Viracta Therapeutics stock.
Viracta Therapeutics, Inc. (VIRX) has issued a series of news releases that trace its evolution from an active clinical-stage precision oncology company to an organization in wind down. Company announcements describe a focus on virus-associated cancers, particularly Epstein-Barr virus (EBV)-positive lymphomas and solid tumors, and provide detailed updates on its lead product candidate, Nana-val, an all-oral combination of nanatinostat and valganciclovir.
News items have covered multiple aspects of Viracta’s development programs, including clinical data from the Phase 2 NAVAL-1 trial in relapsed or refractory EBV-positive lymphomas and from a Phase 1b/2 study in EBV-positive nasopharyngeal carcinoma and other advanced EBV-positive solid tumors. The company has reported positive antitumor activity and a generally well-tolerated safety profile for Nana-val in certain EBV-positive peripheral T-cell lymphoma (PTCL) populations, as well as productive regulatory interactions with the U.S. Food and Drug Administration regarding potential paths to registration.
Corporate and strategic developments are also documented in Viracta’s news flow. Releases describe resource reprioritizations, reductions in force, and a resizing of the board of directors as the company sought to conserve cash and focus on its EBV-positive lymphoma program. Later communications announce the closure of the pivotal NAVAL-1 trial while the board explores strategic alternatives, and ultimately, the termination of employees and a decision to wind down operations, with continued exploration of options for the development programs.
On Stock Titan’s VIRX news page, readers can review this sequence of clinical, regulatory, and corporate updates directly from Viracta’s public disclosures. This provides historical context on Nana-val’s development, Viracta’s precision oncology strategy in EBV-associated cancers, and the subsequent decisions to close trials, explore strategic alternatives, and wind down operations.
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced its Q1 2021 financial results, highlighting its progress in cancer treatment and clinical trials. The company is set to initiate the NAVAL-1 trial for EBV-associated lymphoma this quarter, aiming for multiple NDA filings based on the trial’s success. Financially, Viracta reported a net loss of $79.2 million, or $5.22 per share, but has a strong cash position of approximately $129.2 million. The company expects to end 2021 with over $100 million in cash, supporting operations into 2024.
Viracta Therapeutics announced participation in the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. The Company will present on April 14, 2021, at 3:45 PM ET, focusing on its precision oncology efforts targeting virus-associated malignancies. Viracta's investigational drug, nanatinostat, is in a Phase 2 trial for EBV-positive lymphoma, combined with valganciclovir, and is exploring applications for other EBV-related cancers. For more details, visit www.viracta.com.
Viracta Therapeutics (Nasdaq: VIRX) and XOMA Corporation (Nasdaq: XOMA) announced the acquisition of milestone and royalty rights for two clinical-stage drug candidates through a $13.5 million upfront payment. XOMA may pay up to $20 million in milestone payments. The candidates include DAY101, in a Phase 2 trial for pediatric glioma, and vosaroxin, aimed at treating acute myeloid leukemia. This deal is expected to provide Viracta with non-dilutive capital to support upcoming trials for Epstein-Barr virus-related cancers.
Viracta Therapeutics, Inc. (Nasdaq: VIRX), focused on virus-associated malignancies, announced that CEO Dr. Ivor Royston will present at the Oppenheimer 31st Annual Healthcare Conference from March 16-18, 2021. The presentation is scheduled for March 16 at 2:30 p.m. ET. Investors can access the presentation via a provided webcast link. Viracta is currently evaluating its investigational drug, nanatinostat, in a Phase 2 trial for EBV-positive lymphoma. A replay of the presentation will be available for 90 days on the company's website.
Viracta Therapeutics (Nasdaq: VIRX) announced key leadership changes to enhance their strategic direction in precision oncology. Drs. Stephen Rubino and Barry J. Simon joined the Board of Directors, while Cheryl A. Madsen was appointed Senior VP of Regulatory Affairs. These appointments aim to bolster Viracta's clinical development, particularly for its oral therapy targeting EBV-positive malignancies. Additional promotions include Dan Chevallard as COO and CFO, and other management shifts to support the company's growth as a publicly traded entity.
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand via the conference portal starting at 7 a.m. ET on March 9. The management team will also host one-on-one investor meetings. Viracta focuses on treating virus-associated malignancies with its investigational drug, nanatinostat, currently in a Phase 2 trial for EBV-positive lymphoma.